Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23302128 | 0.84 | GRM2 (0.35) | — | |
| SCHEMBL23302158 | 0.78 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL25843807 | 0.78 | LMNA (0.40) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL25262738 | 0.75 | LMNA (0.40) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL21871418 | 0.75 | TRPA1 (0.45) | IRAK4 | |
| SCHEMBL22606823 | 0.75 | LPL (0.36) | — | |
| SCHEMBL30039346 | 0.75 | MEN1 (0.44) | KDM4EALDH1A1SMN1; SMN2HSD11B1 | |
| SCHEMBL16439291 | 0.74 | PRKCI (0.33) | HSD11B1 | |
| SCHEMBL30037729 | 0.72 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL16806050 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1LMNACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246968-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC | 2024-07-25 | — | — | US | disclosed |
| EP-4329750-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | ASTEX THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| CN-115551500-A | 4-aminobut-2-enamide derivatives and salts thereof | 大鹏药品工业株式会社 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022232320-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-4051266-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021085653-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084765-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | KRAS, NRAS, HRAS | KDM4E 1777/4885ALDH1A1 2807/4885LMNA 3025/4885 |
| US-20240246968-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | KRAS, NRAS, HRAS | KDM4E 3068/4885ALDH1A1 3065/4885LMNA 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.